Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective

Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men

David P. Wilson A B , Alexander Hoare A , David G. Regan A and Matthew G. Law A

A National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW 2010, Australia.

B Corresponding author. Email:

Sexual Health 6(1) 19-33
Submitted: 29 October 2008  Accepted: 11 December 2008   Published: 23 February 2009


Background: We address the research questions: (i) what proportion of new HIV infections is transmitted from people who are (a) undiagnosed, (b) in primary HIV infection (PHI), (c) on antiretroviral therapy?; and (ii) what is the expected epidemiological impact of (a) increasing the proportion of newly acquired HIV infections receiving early treatment, and (b) increasing HIV testing rates? Methods: We used a mathematical model to simulate HIV transmission in the population of men who have sex with men (MSM) in Australia. We calibrated the model using established biological and clinical data and a wide range of Australian MSM epidemiological and behavioural data sources. Results: We estimate that ~19% of all new HIV infections are transmitted from the ~3% of Australian HIV-infected MSM who are in PHI; ~31% of new HIV infections are estimated to be transmitted from the ~9% of MSM with undiagnosed HIV. We estimate that the average number of infections caused per HIV-infected MSM through the duration of PHI is ~0.14–0.28. Conclusions: The epidemiological impact of increasing treatment in PHI would be modest due to insufficient detection of newly-infected individuals. In contrast, increases in HIV testing rates could have substantial epidemiological consequences. The benefit of testing will also increase over time. Promoting increases in the coverage and frequency of testing for HIV could be a highly-effective public health intervention, but the population-level impact of interventions based on promoting early treatment of patients diagnosed in PHI is likely to be small. Treating PHI requires further evaluation of its long-term effects on HIV-infected individuals.

Additional keywords: Australia, early treatment, HIV/AIDS, men who have sex with men, testing.


[1]  Fisher M Pao D Murphy G Dean G McElborough D Homer G et al 2007 Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. AIDS 21 2309 14

[2]  Dougan S Elford J Chadborn TR Brown AE Roy K Murphy G et al 2007 Does the recent increase in HIV diagnoses among men who have sex with men in the UK reflect a rise in HIV incidence or increased uptake of HIV testing? Sex Transm Infect 83 120 5

[3]  Dukers NH Spaargaren J Geskus RB Beijnen J Coutinho RA Fennema HS 2002 HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS 16 F19 24 doi:10.1097/00002030-200207050-00001

[4]  The UK Collaborative Group for HIV and STI Surveillance. Mapping the Issues: HIV and Other Sexually Transmitted Infections in the United Kingdom in 2004. London: Health Promotion Agency, Centre for Infections; 2005.

[5]  Sanders GD Taira AV 2003 Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 37 48

[6]  Grulich AE Kaldor J 2008 Trends in HIV incidence in homosexual men in developed countries. Sex Health 5 113 18

[7]  Apoola A Ahmad S Radcliffe K 2002 Primary HIV infection. Int J STD AIDS 13 71 8 doi:10.1258/0956462021924613

[8]  Quinn TC Wawer MJ Sewankambo N Serwadda D Li C Wabwire-Mangen F et al 2000 Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342 921 9 doi:10.1056/NEJM200003303421303

[9]  Kaufmann GR Cunningham P Kelleher AD Zaunders J Carr A Vizzard J et al 1998 Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis 178 1812 5 doi:10.1086/314480

[10]  Richardson BA Mbori-Ngacha D Lavreys L John-Stewart GC Nduati R Panteleeff DD et al 2003 Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol 77 7120 3 doi:10.1128/JVI.77.12.7120-7123.2003

[11]  Schacker TW Hughes JP Shea T Coombs RW Corey L 1998 Biological and virologic characteristics of primary HIV infection. Ann Intern Med 128 613 20

[12]  Fidler S Fox J Porter K Weber J 2008 Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis 21 4 10

[13]  May M Sterne JA Sabin C Costagliola D Justice AC Thiebaut R et al 2007 Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21 1185 97

[14]  The Australian HIV Observational Database 2001 Time trends in antiretroviral treatment use in Australia. Venereology 14 162 8

[15]  National Centre in HIV Epidemiology and Clinical Research. Australian HIV Observational Database Annual Report. Sydney: National Centre in HIV Epidemiology and Clinical Research; 2006.

[16]  Falster K Gelgor L Shaik A Zablotska I Prestage G Grierson J et al 2008 Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment. Sex Health 5 131 54

[17]  Vernazza PL Gilliam BL Dyer J Fiscus SA Eron JJ Frank AC et al 1997 Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 11 987 93 doi:10.1097/00002030-199708000-00006

[18]  Vernazza PL Troiani L Flepp MJ Cone RW Schock J Roth F et al 2000 Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 14 117 21 doi:10.1097/00002030-200001280-00006

[19]  Zhang H Dornadula G Beumont M Livornese L Jr Van Uitert B Henning K et al 1998 Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 339 1803 9 doi:10.1056/NEJM199812173392502

[20]  Van de Ven P Mao L Fogarty A Rawstorne P Crawford J Prestage G et al 2005 Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 19 179 84

[21]  National Centre in HIV Social Research. Annual Report of Trends in Behaviour. Sydney: University of New South Wales; 2006.

[22]  Marks G Crepaz N Senterfitt JW Janssen RS 2005 Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 39 446 53

[23]  Cleary PD Van Devanter N Rogers TF Singer E Shipton-Levy R Steilen M et al 1991 Behavior changes after notification of HIV infection. Am J Public Health 81 1586 90 doi:10.2105/AJPH.81.12.1586

[24]  Colfax GN Buchbinder SP Cornelisse PG Vittinghoff E Mayer K Celum C 2002 Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 16 1529 35 doi:10.1097/00002030-200207260-00010

[25]  McCusker J Stoddard AM Mayer KH Zapka J Morrison C Saltzman SP 1988 Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men. Am J Public Health 78 462 7 doi:10.2105/AJPH.78.4.462

[26]  Saah AJ Hoover DR Weng S Carrington M Mellors J Rinaldo CR Jr et al 1998 Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. AIDS 12 2107 13 doi:10.1097/00002030-199816000-00005

[27]  Smith DK Warren DL Vlahov D Schuman P Stein MD Greenberg BL et al 1997 Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol 146 459 69

[28]  Valleroy LA MacKellar DA Karon JM Rosen DH McFarland W Shehan DA et al 2000 HIV prevalence and associated risks in young men who have sex with men. Young Men’s Survey Study Group. JAMA 284 198 204

[29]  Grierson J , Thorpe R , Pitts M . HIV Futures 5: Life as we know it. Monograph series number 60. Melbourne: The Australian Research Centre in Sex, Health and Society, Latrobe University, Melbourne, Australia; 2006.

[30]  National Centre in HIV Social Research. NSW, VIC and QLD Gay Periodic Surveys. 1998–2006. Sydney: National Centre in HIV Social Research, University of New South Wales; 2006.

[31]  Wilson DP , Hoare A , Regan DG , Wand H , Law M . Mathematical models to investigate recent trends in HIV notifications among men who have sex with men in Australia. Sydney: National Centre in HIV Epidemiology and Clinical Research; 2008.

[32]  Hoare A Wilson DP Regan DG Kaldor J Law MG 2008 Using mathematical modelling to help explain the differential increase in HIV incidence in New South Wales, Victoria and Queensland: the importance of other STIs. Sex Health 5 169 87 doi:10.1071/SH07099

[33]  Anderson RM , May RM . Infectious Diseases of Humans: Dynamics and Control. New York: Oxford University Press; 1991.

[34]  Richters J . HIV/AIDS, Hepatitis C & Related Diseases in Australia: Annual Report of Behaviour. Sydney: National Centre in HIV Social Research, University of New South Wales; 2006.

[35]  Hoare A Regan DG Wilson DP 2008 Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theor Biol Med Model 5 4 doi:10.1186/1742-4682-5-4

[36]  Prestage G Ferris J Grierson J Thorpe R Zablotska I Imrie J et al 2008 Homosexual men in Australia: population, distribution and HIV prevalence. Sex Health 5 97 102 doi:10.1071:SH07080 .

[37]  Grulich AE de Visser RO Smith AMA Rissel CE Richters J 2003 Sexually transmissible infection and blood-borne virus history in a representative sample of adults. Aust NZ J Public Health 27 234 41 doi:10.1111/j.1467-842X.2003.tb00814.x

[38]  Anderson RM , May RM . Infectious Diseases of Humans. Oxford: Oxford University Press; 1991.

[39]  Jacquez JA Koopman JS Simon CP Longini IM Jr 1994 Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 7 1169 84

[40]  Vernazza P Hirschel B Bernasconi E Flepp M 2008 Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitment antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bulletin des médecins suisses 89 165 169

[41]  Kinloch-De Loes S Hirschel BJ Hoen B Cooper DA Tindall B Carr A et al 1995 A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 333 408 13

[42]  Smith DE Walker BD Cooper DA Rosenberg ES Kaldor JM 2004 Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 18 709 18 doi:10.1097/00002030-200403260-00001

[43]  Fidler S Fox J Touloumi G Pantazis N Porter K Babiker A et al 2007 Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS 21 1283 91 doi:10.1097/QAD.0b013e3280b07b5b

[44]  Goujard C Bonarek M Meyer L Bonnet F Chaix ML Deveau C et al 2006 CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42 709 15 doi:10.1086/500213

[45]  Hecht FM Wang L Collier A Little S Markowitz M Margolick J et al 2006 A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 194 725 33 doi:10.1086/506616

[46]  Lampe FC Porter K Kaldor J Law M Kinloch-de Loes S Phillips AN 2007 Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther 12 189 93

[47]  Streeck H Jessen H Alter G Teigen N Waring MT Jessen A et al 2006 Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 194 734 9

[48]  Hoen B Cooper DA Lampe FC Perrin L Clumeck N Phillips AN et al 2007 Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 45 381 90 doi:10.1086/519428

[49]  Kinloch-de Loes S Hoen B Smith DE Autran B Lampe FC Phillips AN et al 2005 Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 192 607 17 doi:10.1086/432002

[50]  Hammer SM Saag MS Schechter M Montaner JS Schooley RT Jacobsen DM et al 2006 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 827 43 doi:10.1001/jama.296.7.827

[51]  Prestage G , Hudson J , Bradley J , Down I , Sutherland R , Corrigan N et al TOMS: Three or More Study. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; 2008.

[52]  National Centre in HIV Social Research Annual Report. Sydney: University of New South Wales; 2006.

[53]  Fogarty A , Mao L , Zablotska I , Salter M , Santana H , Prestage G et al The Health in Men and Positive Health cohorts: A comparison of trends in the health and sexual behaviour of HIV-negative and HIV-positive gay men, 2002–2005, National Centre in HIV Social Research Annual Report of Trends in Behaviour. Sydney: University of New South Wales; 2006.

[54]  Mao L Crawford JM Hospers HJ Prestage GP Grulich AE Kaldor JM et al 2006 “Serosorting” in casual anal sex of HIV-negative gay men is noteworthy and is increasing in Sydney, Australia. AIDS 20 1204 6 doi:10.1097/01.aids.0000226964.17966.75

[55]  Davis KR Weller SC 1999 The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 31 272 9 doi:10.2307/2991537

[56]  Weller SC Davis KR 2002 Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev CD003255

[57]  Pinkerton SD Abtramson PR 1997 Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 44 1303 12

[58]  Weller SC 1993 A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Soc Sci Med 36 1635 44 doi:10.1016/0277-9536(93)90352-5

[59]  Fitch TJ Stine C Hagar DW Mann J Adam MB McIlhaney J 2002 Condom effectiveness: factors that influence risk reduction. Sex Transm Dis 29 811 7 doi:10.1097/00007435-200212000-00013

[60]  Rangsin R Chiu J Khamboonruang C Sirisopana N Eiumtrakul S Brown AE et al 2004 The natural history of HIV-1 infection in young Thai men after seroconversion. J Acquir Immune Defic Syndr 36 622 9 doi:10.1097/00126334-200405010-00011

[61]  Simon V Ho DD Abdool Karim Q 2006 HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368 489 504 doi:10.1016/S0140-6736(06)69157-5

[62]  Sarr AD Eisen G Gueye-Ndiaye A Mullins C Traore I Dia MC et al 2005 Viral dynamics of primary HIV-1 infection in Senegal, West Africa. J Infect Dis 191 1460 7 doi:10.1086/429409

[63]  Rodriguez RJ Dayhoff DE Chang G Cassol SA Birx DL Artenstein AW et al 1997 Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 15 49 53

[64]  Lavreys L , Overbaugh J , Baeten J , Panteleeff D , Martin H , Ogweno G et al Viral load during primary HIV-1 infection in a cohort of female commercial sex workers in Mombasa, Kenya. Proceedings of the 13th International AIDS Conference, 2000 July13; Durban, South Africa: Monduzzi Editore; MoPeB2247.

[65]  Sabin CA Devereux H Phillips AN Hill A Janossy G Lee CA et al 2000 Course of viral load throughout HIV-1 infection. J Acquir Immune Defic Syndr 23 172 7

[66]  Swindells S Evans S Zackin R Goldman M Haubrich R Filler SG et al 2002 Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 30 154 8

[67]  Anekthananon T Ratanasuwan W Techasathit W Sonjai A Suwanagool S 2004 Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 87 760 7

[68]  Bonjoch A Paredes R Domingo P Cervantes M Pedrol E Ribera E et al 2006 Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 22 321 9

[69]  Yozviak JL Doerfler RE Woodward WC 2001 Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice. HIV Clin Trials 2 474 6 doi:10.1310/T0RR-TGY0-8QWB-8YT2

[70]  Blower S Bodine E Kahn J McFarland W 2005 The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 19 1 14 doi:10.1097/00002030-200501030-00001

[71]  Zhang H Dornadula G Beumont M Livornese L Jr Van Uitert B Henning K et al 1998 Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 339 1803 9 doi:10.1056/NEJM199812173392502

[72]  Vittinghoff E Douglas J Judson F McKirnan D MacQueen K Buchbinder SP 1999 Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 150 306 11

[73]  DeGruttola V Seage GR 3rd Mayer KH Horsburgh CR Jr 1989 Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 42 849 56

[74]  Varghese B Maher JE Peterman TA Branson BM Steketee RW 2002 Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 29 38 43 doi:10.1097/00007435-200201000-00007

[75]  Chesson HW Pinkerton SD Voigt R Counts GW 2003 HIV infections and associated costs attributable to syphilis coinfection among African Americans. Am J Public Health 93 943 8 doi:10.2105/AJPH.93.6.943

[76]  Royce RA Sena A Cates W Jr Cohen MS 1997 Sexual transmission of HIV. N Engl J Med 336 1072 8 doi:10.1056/NEJM199704103361507

[77]  Johnson AM Petherick A Davidson SJ Brettle R Hooker M Howard L et al 1989 Transmission of HIV to heterosexual partners of infected men and women. AIDS 3 367 72

[78]  McCormick AW Walensky RP Lipsitch M Losina E Hsu H Weinstein MC et al 2007 The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 44 1115 22

[79]  Grulich AE Cunningham P Munier ML Prestage G Amin J Ringland C et al 2005 Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia. Sex Health 2 13 8 doi:10.1071/SH04029

[80]  Jin F Prestage GP Kippax SC Pell CM Donovan BJ Kaldor JM et al 2005 Epidemic syphilis among homosexually active men in Sydney. Med J Aust 183 179 83

[81]  Bautista CT Sanchez JL Montano SM Laguna-Torres VA Lama JR Sanchez JL et al 2004 Seroprevalence of and risk factors for HIV-1 infection among South American men who have sex with men. Sex Transm Infect 80 498 504

[82]  Fleming DT Wasserheit JN 1999 From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 75 3 17

[83]  Galvin SR Cohen MS 2004 The role of sexually transmitted diseases in HIV transmission. 2 33 42

[84]  Piot P Laga M. 1989 Genital ulcers, other sexually transmitted diseases, and the sexual transmission of HIV. 298 623 624

[85]  Rottingen JA Cameron DW Garnett GP 2001 A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 28 579 97

[86]  Simonsen JN Cameron DW Gakinya MN Ndinya-Achola JO D’Costa LJ Karasira P et al 1988 Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. N Engl J Med 319 274 8

[87]  Read TRH Hocking J Sinnott V Hellard M 2007 Rick factors for incident HIV infection in men having sex with men: a case-control study. Sex Health 4 35 9

[88]  Crawford JM Kippax SC Mao L Van de Ven PG Prestage GP Grulich AE et al 2006 Number of risk acts by relationship status and partner serostatus: Findings from the HIM cohort of homosexually active men in Sydney, Australia. AIDS Behav 10 325 31 doi:10.1007/s10461-005-9057-3

[89]  MAP Workshop. 1993 Extending public health surveillance of HIV infection: information from a five cohort workshop. MAP Workshop (Multi-cohort Analysis Project). Stat Med 12 2065 85 doi:10.1002/sim.4780122203

[90]  Marker paths. 1993 MAP Workshop (Multi-cohort Analysis Project). Stat Med 12 2099 126 doi:10.1002/sim.4780122205

[91]  Law MG Prestage G Grulich A Van de Ven P Kippax S 2001 Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 15 1287 94 doi:10.1097/00002030-200107060-00011

[92]  Kilmarx PH Limpakarnjanarat K Kaewkungwal J Srismith R Saisorn S Uthaivoravit W et al 2000 Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. J Infect Dis 181 1598 606 doi:10.1086/315469

[93]  Bonnet F Morlat P Chene G Mercie P Neau D Chossat I et al 2002 Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998–1999. 3 195 199

[94]  Keiser O Taffe P Zwahlen M Battegay M Bernasconi E Weber R et al 2004 All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 18 1835 43

[95]  Lewden C Raffi F Cuzin L Cailleton V Vilde JL Chene G et al 2002 Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiproteases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study. J Infect Dis 186 710 4 doi:10.1086/342047

[96]  Petoumenos K Law MG 2006 Risk factors and causes of death in the Australian HIV Observational Database. Sex Health 3 103 12 doi:10.1071/SH05045

[97]  Krentz HB Kliewer G Gill MJ 2005 Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. 6 99 106

[98]  Luo K Law M Kaldor JM McDonald AM Cooper DA 1995 The role of initial AIDS-defining illness in survival following AIDS. AIDS 9 57 63

[99]  Costello C Nelson KE Suriyanon V Sennun S Tovanabutra S Heilig CM et al 2005 HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol 34 577 84 doi:10.1093/ije/dyi023

[100]  Li Y McDonald AM Dore GJ Kaldor JM 2000 Improving survival following AIDS in Australia, 1991–1996. National HIV Surveillance Committee. AIDS 14 2349 54 doi:10.1097/00002030-200010200-00016

[101]  Wilson DP Kahn J Blower SM 2006 Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide. Proc Natl Acad Sci USA 103 14228 33 doi:10.1073/pnas.0509689103

[102]  Barbour JD Hecht FM Wrin T Segal MR Ramstead CA Liegler TJ et al 2004 Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 190 251 6 doi:10.1086/422036

[103]  Egger M Hirschel B Francioli P Sudre P Wirz M Flepp M et al 1997 Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. 315 1194 1199

[104]  Egger M May M Chene G Phillips AN Ledergerber B Dabis F et al 2002 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 119 29

[105]  Hogg RS Heath KV Yip B Craib KJ O’Shaughnessy MV Schechter MT et al 1998 Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279 450 4 doi:10.1001/jama.279.6.450

[106]  Mocroft A Vella S Benfield TL Chiesi A Miller V Gargalianos P et al 1998 Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352 1725 30 doi:10.1016/S0140-6736(98)03201-2

[107]  Palella FJ Jr Delaney KM Moorman AC Loveless MO Fuhrer J Satten GA et al 1998 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 853 60 doi:10.1056/NEJM199803263381301

[108]  Wilson DP Law MG Grulich AE Cooper DA Kaldor JM 2008 Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 372 314 20 doi:10.1016/S0140-6736(08)61115-0

[109]  Smith RJ Blower SM 2004 Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infect Dis 4 636 9 doi:10.1016/S1473-3099(04)01148-X

Export Citation